Adial Pharma Touts Positive Preclinical Data From Chronic Pain Candidate

  • Adial Pharmaceuticals Inc's ADIL subsidiary, Purnovate Inc, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain.
  • The study was conducted in four groups of ten rats that underwent surgical injury of the sciatic nerve. 
  • At 30 minutes post-dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen (APAP) doses did not have a significant effect. 
  • PNV-5030 also demonstrated a 49% improvement in pain reduction over acetaminophen.
  • Also ReadAdial Pharma's Subsidiary Shows Encouraging Preclinical Action For Inflammatory Bowel Disease Candidate
  • At 60 minutes post-dose, PNV-5030 reduced pain by 76% compared to the control group. PNV-5030 also demonstrated a 53% improvement in pain reduction over acetaminophen.
  • At 120 minutes post-dose, PNV-5030 reduced pain by 62% compared to the control group and by 56% at 180 minutes post-dose.
  • PNV-5030 has been tested to be more than 1000-fold selective over the adenosine A1 receptor. Historically, when selectivity has been achieved over the A1 receptor, water solubility has decreased, making biodistribution challenging. 
  • However, PNV-5030 has demonstrated more than 50 times greater solubility than other known selective adenosine compounds of the same class and has shown it achieves the necessary biodistribution.
  • Price Action: ADIL shares are down 1.28% at $0.37 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!